Alector (NASDAQ:ALEC) CFO Neil Lindsay Berkley Sells 29,251 Shares

Alector, Inc. (NASDAQ:ALEC) CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the sale, the chief financial officer directly owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alector Stock Performance

NASDAQ:ALEC opened at $2.46 on Friday. The company has a quick ratio of 5.26, a current ratio of 5.26 and a debt-to-equity ratio of 0.80. Alector, Inc. has a twelve month low of $1.09 and a twelve month high of $3.40. The company has a fifty day moving average of $1.91 and a 200-day moving average of $2.06. The firm has a market capitalization of $274.68 million, a P/E ratio of -2.24 and a beta of 0.65.

Alector (NASDAQ:ALEC) last issued its earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. The business had revenue of $3.32 million for the quarter, compared to analyst estimates of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. As a group, sell-side analysts anticipate that Alector, Inc. will post -0.87 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jane Street Group LLC lifted its position in Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock valued at $316,000 after acquiring an additional 11,618 shares in the last quarter. Strs Ohio bought a new stake in Alector during the 1st quarter worth approximately $126,000. Geode Capital Management LLC raised its stake in shares of Alector by 1.0% in the second quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company’s stock worth $2,775,000 after purchasing an additional 19,970 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Alector in the second quarter worth approximately $30,000. Finally, XTX Topco Ltd lifted its holdings in shares of Alector by 125.2% in the second quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock valued at $103,000 after purchasing an additional 40,767 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ALEC shares. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Alector presently has a consensus rating of “Hold” and an average price target of $3.62.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.